Another trial (NCT05119335) examines NKT2152, a HIF2α inhibitor, in advanced (ccRCC), exploring its potential to disrupt cancer growth by inhibiting both HIF2α and CDK4/6 (98). This evidence concerns the gene EPAS1 and cancer.